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Background: Hypoxia is a common characteristic of solid tumors associated with reduced response to radio- and
chemotherapy, therefore increasing the probability of tumor recurrence. The aim of this study was to identify new
mechanisms responsible for hypoxia-induced resistance in breast cancer cells.
Methods: MDA-MB-231 and HepG2 cells were incubated in the presence of taxol or etoposide respectively under
normoxia and hypoxia and apoptosis was analysed. A whole transcriptome analysis was performed in order to
identify genes whose expression profile was correlated with apoptosis. The effect of gene invalidation using siRNA
was studied on drug-induced apoptosis.
Results: MDA-MB-231 cells incubated in the presence of taxol were protected from apoptosis and cell death by
hypoxia. We demonstrated that TMEM45A expression was associated with taxol resistance. TMEM45A expression
was increased both in MDA-MB-231 human breast cancer cells and in HepG2 human hepatoma cells in conditions
where protection of cells against apoptosis induced by chemotherapeutic agents was observed, i.e. under hypoxia
in the presence of taxol or etoposide. Moreover, this resistance was suppressed by siRNA-mediated silencing of
TMEM45A. Kaplan Meier curve showed an association between high TMEM45A expression and poor prognostic in
breast cancer patients. Finally, TMEM45 is highly expressed in normal differentiated keratinocytes both in vitro and
in vivo, suggesting that this protein is involved in epithelial functions.
Conclusion: Altogether, our results unravel a new mechanism for taxol and etoposide resistance mediated by
TMEM45A. High levels of TMEM45A expression in tumors may be indicative of potential resistance to cancer
therapy, making TMEM45A an interesting biomarker for resistance.
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The development of therapy resistance continues to be
a major problem in the treatment of patients with can-
cer. Treatment failure has been very recently identified
as one of the four major issues in cancer research
[1]. Identification of underlying mechanisms is thus
of great value.
Some mechanisms underlying cancer resistance to
chemotherapy have been unraveled [2]. One of the well
characterized cellular factors of resistance is the overex-
pression of the P-glycoprotein encoded by the MDR1
gene [3]. This protein is an efflux pump that expulses* Correspondence: carine.michiels@fundp.ac.be
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reproduction in any medium, provided the orthe chemotherapeutic drug out of the tumor cells. Other
efflux pumps have been identified, all belonging to the
ABC (ATP-binding cassette) transporter family, which
expression may also play a role in inducing chemoresis-
tance [4]. Numerous molecules inhibiting efflux pump
activity have been tested but without real therapeutic
success or with unacceptable toxicity [5]. Other import-
ant causes of resistance are the molecular alterations of
the drug targets. Other resistance mechanisms include
enhanced DNA repair, loss of p53, inhibition of apop-
tosis, activation of cell survival pathways caused by
mutations or epigenetic alterations occurring in the con-
text of genetic instability (selection of resistant cells) [6].
There are however still numerous open questionsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Flamant et al. BMC Cancer 2012, 12:391 Page 2 of 16
http://www.biomedcentral.com/1471-2407/12/391regarding the mechanisms allowing cancer cells to
escape drug-induced toxic effects.
Tumor hypoxia is often associated with resistance to
chemotherapy [7] and radiotherapy [8], with tumor pro-
gression, aggressiveness and metastasis, and therefore with
an increased probability of tumor recurrence [9]. Identifica-
tion of the mechanisms responsible for this protection
would therefore have significant clinical benefits.
Hypoxia, the reduction of the normal level of tissue
oxygen tension, is a common feature of solid tumors
caused by of the abnormal vascular network and the high
proliferation rate of cancer cells [10]. Intratumoral hyp-
oxia develops when cells are located further than 100–
180 μm from a functional blood vessel. Indeed, oxygen is
unable to diffuse beyond this distance from a capillary
before it is completely metabolized.
It was shown that up to 50-60% of locally advanced
solid tumors may exhibit hypoxic and/or anoxic tissue
areas heterogeneously distributed within the tumor mass
[11]. Hypoxia occurs in breast tumors, as in other solid
tumors, mostly because of tumor outgrowing of the
existing vasculature (reviewed in [12]). In breast cancer,
hypoxia has been correlated with bad prognosis. Indeed,
HIF-1α [13] or HIF-2α [14] expression, as surrogate mar-
kers of tumor hypoxia, correlates with distant recurrence
and poor outcome. Furthermore, expression profiles of
the hypoxic markers, GLUT1 and CAIX, also correlate
with adverse prognostic factors in breast cancer [15].
Hepatocellular carcinomas were also reported to display
hypoxia [16]. Hypoxic regions have also been identified
in tumors of many other histotypes such as brain tumors
[17,18], head and neck [19] or cervical [20], endometrial
[21] and lung [22] cancers.
It is now thought that hypoxia, according to its sever-
ity, can either promote apoptosis and cell death or con-
trariwise induce cell growth and survival by provoking
an adaptive response. To survive in the hypoxic environ-
ment which takes place in the centre of solid tumors,
cells co-opt adaptive mechanisms leading to a variety of
biological responses, i.e. switching to a glycolytic metab-
olism, proliferation, evasion of apoptosis, obtaining a
limitless replicative potential, induction of angiogenesis,
invasion of the immune system and tissue invasion and
metastasis [23].
If some mechanisms underlying the hypoxia-induced
radio- and chemoresistance begin to be understood, the ac-
tual actors of the protection still need to be identified. The
aim of this study was to characterize the mechanisms
underlying the hypoxia protection against paclitaxel-
induced apoptosis observed in MDA-MB-231 cells, but
also the hypoxia protection against etoposide-induced
apoptosis previously observed in HepG2 cells [24,25].
We exposed MDA-MB-231 cells to two chemothera-
peutics agents, paclitaxel and epirubicin, used asapoptosis inducers. These two drugs belong respectively
to the class of taxoids and anthracyclines, which are con-
sidered to be the most active agents in the treatment of
breast cancer [26]. Paclitaxel binds to microtubules and
causes their stabilization, inducing cell cycle arrest at
G2/M mitotic phase followed by apoptosis. It also
induces modulation of the expression or posttransla-
tional modification of pro- and anti-apoptotic proteins
[27]. Epirubicin HCl, a derivative of doxorubicin, leads to
the inhibition of DNA and RNA synthesis by intercal-
ation between base pairs of the DNA/RNA. It also inhi-
bits topoisomerase II by stabilizing DNA-topoisomerase
complex, resulting in DNA damage and induction of
apoptosis and cell death [28]. It was also proposed that
epirubicin could induce formation of reactive oxygen
species promoting apoptosis [29]. As a second experi-
mental model, we used etoposide to induce cell death in
HepG2 cells. This antineoplastic drug functions as a
topoisomerase II inhibitor, hence inducing double strand
breaks in DNA, leading to the activation of apoptosis in
a p53 dependent manner [30]. The biochemical and mo-
lecular mechanisms of apoptosis activation by these
drugs are complex and are still under investigation.
We recently highlighted two mechanisms by which
hypoxia protects cells from apoptosis via the activation
of hypoxia-inducible factor-1 (HIF-1) and AP-1 tran-
scription factors and the consecutive changes in expres-
sion of anti- and pro-apoptotic proteins [31]. Here, we
investigated other changes in gene expression that may
explain how hypoxia exerts its protective effect against
paclitaxel induced-apoptosis.
Results
Hypoxia protects MDA-MB-231 cells against paclitaxel-
induced apoptosis
Recent studies showed that hypoxia confers resistance
against chemotherapy-induced apoptosis in cancer cells
[32,33]. We have shown previously that hypoxia protects
human breast cancer MDA-MB-231 cells against
paclitaxel-induced apoptosis [31]. To confirm the effect
of hypoxia on paclitaxel- and epirubicin-induced apop-
tosis, we assessed caspase 3 activity and cell death in
MDA-MB-231 cells incubated with these drugs under
normoxia or hypoxia (Figure 1A, B). 50 μM paclitaxel
and 10 μM epirubicin were chosen, from concentration
titration curve, to induce a marked induction of apop-
tosis in order to be able to observe a protective effect
but not a too high induction of ell death that could no
longer be inhibited (data not shown). Hypoxia per se did
not induce apoptosis or cell death since no increase in
caspase 3 activity or LDH release was observed. Pacli-
taxel and epirubicin triggered apoptosis and cell death as
shown by an increase in caspase 3 activity and in LDH
release in normoxia. Hypoxia did not modify epirubicin-
Figure 1 Effect of hypoxia on paclitaxel or epirubicin-induced apoptosis and cell death. MDA-MB-231 cells were incubated under normoxic
(N) or hypoxic (H) conditions with or without paclitaxel (tax, 50 μM) or epirubicin (epi, 10 μM) for 16 hours. (A) Caspase 3 activity was assayed by
measuring free AFC released from the cleavage of the caspase 3 specific substrate Ac-DEVD-AFC. Results are expressed in fluorescence intensity,
as mean± 1 SD (n = 3). (B) After the incubation, LDH release was assessed. Results are expressed as mean± 1 SD (n = 3). (C) After the incubation,
DNA fragmentation was assayed using an ELISA for soluble nucleosomes (Cell Death Detection Elisa, Roche). Results are expressed as mean± 1 SD
(n = 3). (D) Nuclear fragmentation was observed after nuclei labeling with DAPI using non-confocal fluorescent microscope (40x magnification).
Fragmented nuclei are pointed by arrows. N.S. = non significantly different from control, ** = significantly different from control (p < 0.01),
*** = significantly different from control (p < 0.001) ; N.S. = no significant difference between N epi and H epi, ## = significant difference between
N tax and H tax (p < 0.01). ### = significant difference between N tax and H tax (p < 0.001).
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inhibited paclitaxel-induced increase in caspase 3 activity
and LDH release. Hypoxia also inhibited paclitaxel-
induced increase in caspase 3 activity at 100 μM (data
not shown).
DNA fragmentation was also assessed. An increase in
DNA fragmentation was observed in the presence ofpaclitaxel under normoxia, which was significantly
decreased by hypoxia (Figure 1C). No effect of epirubicin
was detected, probably because an incubation of 16 hours
was not long enough to induce the later stages of apop-
tosis. Nucleus morphology was observed in fluorescence
microscopy after cell labelling with DAPI. Fragmented
nuclei were observed in cells exposed to paclitaxel under


























H tax / N tax P values H epi / N epi
N H N tax H tax N epi H epi H tax vs N tax
SPAG4 1 0.23 84.19 0.07 0.73 0.14 38.57 0.17 1.86 0.07 1.47 0.4 52.76 4.88E-05 0.79
ALDOC 1 0.39 91.10 0.17 0.46 0.07 22.20 0.23 0.73 0.16 0.86 0.2 48.31 0.0002552 1.18
ANGPTL4 1 0.03 53.47 0.19 0.80 0.19 26.54 0.35 0.67 0.04 0.69 0.0 33.10 0.0006633 1.02
PFKFB4 1 0.12 12.11 0.05 0.51 0.03 11.73 0.15 0.04 0.09 0.04 0.0 23.12 0.0001621 0.94
C10orf10
probe set 1
1 0.15 69.43 0.30 0.86 0.03 18.27 0.43 0.87 0.03 0.87 0.0 21.19 0.0019277 1.00
TMEM45A 1 0.59 106.19 0.01 5.13 0.29 86.65 0.21 8.80 0.31 10.01 0.1 16.88 0.0002627 1.14
RASSF4
probe set 1
1 0.09 11.21 0.15 0.40 0.02 5.86 0.32 0.15 0.74 0.06 0.2 14.65 0.0004547 0.42
ANKRD37 1 0.18 21.08 0.15 1.92 0.14 21.56 0.23 0.19 0.70 0.14 0.1 11.26 0.0001464 0.71
PDK1
probe set 1
1 0.05 8.58 0.13 1.12 0.03 9.01 0.26 3.03 0.07 3.34 0.0 8.06 0.0004021 1.10
PDK1
probe set 2
1 0.18 9.08 0.27 1.36 0.16 10.98 0.40 4.13 0.24 3.56 0.0 8.05 0.0039759 0.86
BNIP3
probe set 1
1 0.05 10.33 0.13 1.39 0.07 10.62 0.20 1.85 0.09 1.87 0.1 7.66 0.0004483 1.01
NDRG1 1 0.21 10.01 0.08 1.23 0.15 9.28 0.12 0.35 0.23 0.27 0.0 7.51 6.10E-05 0.78
RASSF4
probe set 2
1 0.03 9.04 0.10 0.73 0.02 5.05 0.37 0.79 0.06 0.81 0.1 6.91 0.0023704 1.03
AK3L1 1 0.04 3.91 0.07 0.36 0.08 2.26 0.08 1.84 0.05 2.34 0.0 6.32 0.0003084 1.27
WFDC3 1 0.23 8.94 0.31 0.39 0.24 2.46 0.12 0.53 0.37 1.04 0.3 6.28 0.0001468 1.95
P4HA1 1 0.14 10.23 0.05 1.00 0.09 5.60 0.17 1.66 0.15 1.56 0.1 5.59 0.0001797 0.94
MALL 1 0.11 2.64 0.16 0.22 0.19 1.23 0.09 1.07 0.24 1.15 0.1 5.54 0.0001154 1.07
RAB20 1 0.09 4.65 0.02 0.63 0.19 3.33 0.22 0.16 0.23 0.08 0.0 5.32 0.0003267 0.48
EGLN3 1 0.02 13.74 0.17 1.01 0.00 5.14 0.35 0.94 0.09 1.00 0.0 5.09 0.0034448 1.06
FUT11 1 0.23 5.60 0.12 0.49 0.22 2.46 0.16 0.32 0.30 0.21 0.3 5.02 0.0037602 0.67
BNIP3
probe set 2
1 0.09 6.22 0.07 1.25 0.09 6.18 0.13 1.48 0.08 1.58 0.0 4.93 4.93E-05 1.07
PLOD2 1 0.04 7.09 0.11 1.13 0.05 5.45 0.25 2.83 0.20 3.10 0.0 4.83 0.0005200 1.10
PGF 1 0.18 12.21 0.05 0.61 0.22 2.87 0.11 0.39 0.30 0.22 0.2 4.69 0.0008395 0.56
ENO2 1 0.11 5.46 0.06 0.90 0.13 4.17 0.08 2.01 0.10 2.32 0.0 4.66 0.0001298 1.15
TNFSF10 1 0.13 4.11 0.19 0.90 0.52 4.15 0.36 0.98 0.14 1.01 0.0 4.63 0.0026329 1.03














































Table 1 Gene expression profiling in MDA-MB-231 cells incubated with or without paclitaxel (tax) or epirubicin (epi) un er normoxic (N) or hypoxic
(H) conditions (Continued)
PFKFB3 1 0.00 5.50 0.10 1.17 0.11 5.24 0.32 0.59 0.27 0.33 0.1 4.47 0.0019571 0.56
ANKZF1 1 0.11 6.70 0.07 1.31 0.16 5.77 0.17 0.59 0.15 0.58 0.1 4.40 0.0012567 0.98
JMJD1A 1 0.11 5.36 0.10 2.12 0.02 8.93 0.19 0.35 0.98 0.15 0.2 4.21 0.0017354 0.42
C10orf10
probe set 2
1 0.01 23.38 0.78 1.00 0.00 4.12 0.34 1.01 0.01 1.37 0.4 4.14 0.0020200 1.36
IL24 1 1.42 0.14 0.20 5.70 0.27 0.82 0.60 6.86 1.43 1.07 0.2 0.14 0.0010651 0.16
Cells were incubated in the different conditions for 16 hours before RNA extraction, target preparation, hybridization to Affymetrix HG-U133 Plus 2.0 arrays, washi g and array signal acquisition, as described in Material
an Methods. Each value of the fold induction columns is the mean of three ratio values calculated from three independent experiments. These 31 candidate gene were selected on the basis of their p value (p < 0.005)

























Figure 2 Analysis of TMEM45A gene expression level obtained
with real time PCR and Affymetrix microarrays and effect of
TMEM45A silencing on TMEM45A expression. (A) For Affymetrix
microarray results: cells were incubated under normoxic (N) or
hypoxic (H) conditions with or without paclitaxel (tax, 50 μM) or
epirubicin (epi, 10 μM) for 16 hours before total RNA extraction.
Results are expressed as mean ratios indicating a fold-increase or
decrease in gene expression by comparison with the reference
condition (normoxia) ± 1 SD (n = 3). For Real Time PCR results: after
incubation, total RNA has been extracted and retro-transcribed in
cDNA. A real time PCR has been performed with specific primers for
TMEM45A and for RPL13A, a house-keeping gene. Results are
expressed as mean of induction level by comparison with the
reference condition (normoxia) ± 1 SD (n = 3). (B) Effect of TMEM45A
silencing on TMEM45A expression. MDA-MB-231 cells were
transfected 24 h with TMEM45A siRNA (siRNA) or RISC-free control
siRNA (RF) (50 nM). Cells were then incubated in normoxia or
hypoxia with paclitaxel (tax, 50 μM) for 16 hours. TMEM45A mRNA
expression was quantified by real-time RT-PCR using RPL13A as the
house-keeping gene. Results are expressed in induction level by
comparison with the reference condition, normoxia. (C) Effect of HIF-
1α silencing on TMEM45A expression. MDA-MB-231 cells were
transfected 24 h with HIF1A siRNA (HIF) or RISC-free control siRNA
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http://www.biomedcentral.com/1471-2407/12/391normoxia but neither in cells exposed to paclitaxel under
hypoxia, nor in cells that were not incubated with pacli-
taxel (Figure 1D).
Altogether, these data demonstrated that hypoxia was
able to protect MDA-MB-231 cells against the paclitaxel-
induced apoptosis.
Hypoxia combined with paclitaxel or epirubicin induces
changes in gene expression
In order to identify the mechanism(s) responsible for the
hypoxia-induced protection, Affymetrix whole transcrip-
tome analysis was performed using RNA isolated from
control cells and from cells incubated in the presence of
taxol or epirubicin, both under normoxia and hypoxia.
Experimental triplicates were analyzed for each experi-
mental condition.
Unsupervised hierarchical clustering was performed
without any gene selection in order to group the condi-
tions on the basis of their similarity measured over all
probe sets of the array (Additional file 1: Figure S1).(RF) (50 nM). Cells were then incubated in normoxia or hypoxia for
16 hours. TMEM45A mRNA expression was quantified by real-time
RT-PCR using RPL13A as the house-keeping gene. Results are
expressed in induction level by comparison with the reference
condition, normoxia, as means ± 1 SD (n = 3).Unsupervised cluster analysis using centered correlation
and average linkage showed that control cells were well
separated from drug-treated cells. Moreover, for control
cells and cells incubated in the presence of taxol, hyp-
oxia was separated from normoxia while it was not the
case for epirubicin-treated cells. These results are in good
accordance with the protection of drug-induced apoptosis
brought by hypoxia for paclitaxel but not for epirubicin.
We hypothesized that gene expression modifications in
the different conditions could influence the paclitaxel-
induced apoptosis, leading to cell protection in hypoxia.
We thus compared differences and similarities in gene
expression modifications in these conditions and genes
were sorted to select only those with a high difference in
expression between cells exposed to paclitaxel in nor-
moxia (“N tax”) and cells exposed to paclitaxel under
hypoxia (“H tax”), which could therefore be involved in
the hypoxia-induced protection against paclitaxel-
induced apoptosis.
First of all, the probe sets were ranked in ascending
order of the p values of their differential expression be-
tween “N tax” and “H tax”, and only highly significant
ones with a p value lower than 0.005 were selected. A
second round of selection of probe sets was performed
by keeping only those with a minimum fold change of at
least 4 times between these 2 conditions. Table 1 shows
the 31 probe sets selected on the basis of their p value
and fold change between “N tax” and “H tax”.
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upregulated by hypoxia such as ALDOC, PFKFB4, PDK1,
BNIP3, NDRG1, ENO2, PFKFB3 and JMJD1A. The ex-
pression patterns of 5 genes were validated by qRT-PCR:
for 4 of them (TMEM45A, STC1, FAM26F and GDF15),
the changes in mRNA levels were confirmed. However, noFigure 3 (See legend on next page.)change was detected for S100A10 by real-time RT-PCR
(data not shown).
Interestingly, level of TMEM45A mRNA was increased
more than 16 fold in cells exposed to paclitaxel under
hypoxia compared to cells exposed to paclitaxel under
normoxia and was increased in hypoxic condition with
(See figure on previous page.)
Figure 3 Effect of TMEM45A silencing on the protective effect of hypoxia on paclitaxel-induced apoptosis. 8 h post transfection with
TMEM45A siRNA (siRNA) or RISC-free control siRNA (RF) (50 nM, 24 h), MDA-MB-231 cells were incubated under normoxic (N) or hypoxic (H)
conditions with or without paclitaxel (tax, 50 μM) or epirubicin (epi, 10 μM) for 16 hours. (A) After transfection and incubation, caspase 3 activity
was assayed by measuring free AFC released from the cleavage of the caspase 3 specific substrate Ac-DEVD-AFC. Results are expressed in
fluorescence intensity, as mean± 1 SD (n = 3). (B) After the incubation, DNA fragmentation was assayed using an ELISA for soluble nucleosomes
(Cell Death Detection Elisa, Roche). Results are expressed as mean± 1 SD (n = 3). Statistical analyses were determined independently for the 3
subgroups without siRNA, with anti-TMEM45A siRNA (siRNA) and with RISC-free control siRNA (RF) ; N.S. = non significantly different from control (N,
N siRNA or N RF), ** = significantly different from control (p < 0.01), *** = significantly different from control (p < 0.001) ; N.S. (1) = no significant
difference between N epi and H epi, #, ### = significant difference between (1) N tax and H tax or (2) N epi and H epi (p < 0.05 ; <0.001), N.S. (2) = no
significant difference between H tax and H tax RF, ••= significant difference between N tax and N tax RF (p < 0.01), •••= significant difference
between (1) N tax and N tax siRNA or (2) H tax and H tax siRNA (p < 0.001).
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http://www.biomedcentral.com/1471-2407/12/391or without paclitaxel but not in the presence of epirubi-
cin (Figure 2A). This expression profile was parallel to
the apoptotic profile of cells exposed to these two drugs
under normoxia or hypoxia. This suggested that this pro-
tein could play a role in modulating drug-induced apop-
tosis. TMEM45A encodes a hypothetical transmembrane
protein with unknown function. We thus decided to in-
vestigate further this gene.
TMEM45A is essential to mediate the hypoxia-induced
protection against paclitaxel-induced apoptosis
In order to test the possible role of TMEM45A in the
hypoxia-induced resistance to taxol, its expression was
knocked down in MDA-MB-231 using siRNA. A concen-
tration of 50 nM of siRNA was high enough to strongly
inhibit the mRNA expression of TMEM45A while the
RISC-Free negative control siRNA had no effect
(Figure 2B). TMEM45A has been described to be a HIF-
1 target gene in different types of cancer cells [34]. We
verified that it was also the case in MDA-MB-231 cells.
HIF-1α silencing by siRNA confirmed the role of HIF-1α
since a decreased by more than 80% in the hypoxia-
induced upregulation of TMEM45A mRNA expression
was observed (Figure 2C).
It has to be noted that numerous experiments aimed
to analyze TMEM45A protein expression by western blot
have been performed. Whatever the lysis buffer and the
conditions of antibody incubation with the membrane,
we did not succeed to detect a band corresponding to
the protein (i.e. that is no longer observed in extracts
from cells transfected with the siRNA targeting
TMEM45A mRNA). However, we validated the Sigma
anti-TMEM45A antibody using two approaches: (i)
TMEM45A has been immunoprecipitated from post-
confluent keratinocyte protein extract (see below), using
the anti-TMEM45 antibody. Proteins that were immuno-
precipitated were separated by SDS-PAGE and the gel
area containing proteins between 64 and 98 kDa (i.e. the
approximate apparent molecular weight range observed
for the protein in western blot analysis of extract from
the same cell type) was excised after silver staining of
proteins. Proteins were digested with trypsin, extractedfrom the polyacrylamide gel and analyzed by mass spec-
trometry. TMEM45A was identified in this band, while it
was not present in bands corresponding to negative con-
trols. (ii) TMEM45A cDNA was cloned into the
pDest475 plasmid allowing the expression of a HA-
tagged version of TMEM45A. This plasmid was trans-
fected into MCF-7 cells and cells have been analyzed by
immunofluorescence staining using an anti-HA and the
anti-TMEM45A antibody. Results showed that both anti-
bodies recognized the same vesicular structures within
transfected cells and clearly co-localized (data not
shown). No labeling was observed in untransfected cells
with either of the antibodies (data not shown). From these
results, we concluded that the anti-TMEM45A antibody
from Sigma does recognize specifically the TMEM45A
protein. It is able to detect the protein when expressed in
high quantity (upon artificial overexpression or in post-
confluent keratinocytes (ct in real-time PCR=21–26 with
21 for post-confluent and 26 for subconfluent keratino-
cytes) but not in cells with mild expression (MDA-MB-
231 (ct in real-time PCR=31) or HepG2 cells ((ct in real-
time PCR=29)), possibly because it has a low affinity.
We then investigated if TMEM45A was involved in the
hypoxia-induced resistance to paclitaxel-induced apoptosis.
For that purpose, cells were transfected with TMEM45A or
control siRNA before being incubated under normoxia or
hypoxia in the presence of one or the other chemothera-
peutic agent. If TMEM45A plays an anti-apoptotic role, an
increase in the paclitaxel-induced caspase 3 activity is
expected when inhibited by siRNA. Figure 3A shows that
caspase 3 activity was significantly increased in TMEM45A
siRNA transfected cells incubated with paclitaxel or epiru-
bicin, both under normoxia and hypoxia. The caspase 3 ac-
tivity measured for TMEM45A siRNA transfected cells
incubated with paclitaxel under hypoxia reached a level
much higher than the activity measured for non transfected
cells incubated with paclitaxel in normoxia, indicating addi-
tive effects of hypoxia and of TMEM45A for cell protec-
tion. No modification was observed in cells transfected
with the negative control siRNA.
We confirmed these observations by determining the
effect of TMEM45A silencing on paclitaxel induced
Figure 4 Analysis of TMEM45A gene expression level and effect of TMEM45A silencing on TMEM45A expression and caspase 3 activity
in HepG2 cells. HepG2 cells were incubated under normoxic (N) or hypoxic (H) conditions with or without etoposide (etop, 50 μM) for 16 hours,
8 h post transfection with TMEM45A siRNA (siRNA) or RISC-free control siRNA (RF) (50 nM, 24 h). (A) After transfection and incubation, total RNA
has been extracted and retro-transcribed in cDNA. A real time PCR has been performed with specific primers for TMEM45A and for RPL13A, a
house-keeping gene. Results are expressed in induction level by comparison with the reference condition, normoxia. (B) After transfection and
incubation, caspase 3 activity was assayed by measuring free AFC released from the cleavage of the caspase 3 specific substrate Ac-DEVD-AFC.
Results are expressed in fluorescence intensity, as mean± 1 SD (n = 3). Statistical analyses were determined independently for the 3 subgroups
without siRNA, with TMEM45A siRNA (siRNA) and with RISC-free control siRNA (RF) ; N.S. = non significantly different from control (N, N siRNA or
N RF), ** = significantly different from control (p < 0.01), *** = significantly different from control (p < 0.001) ; N.S. (1) = no significant difference
between N etop and H etop, ### = significant difference between N etop and H etop (p < 0.001), N.S. = no significant difference between (2)
N etop and N etop RF, (3) N etop and N etop siRNA, or (4) H etop and H etop RF, •••= significant difference between H etop and H etop
siRNA (p < 0.001).
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Figure 5 Kaplan-Meier probability of relapse-free survival for
286 patients with lymph-node-negative breast cancer allocated
to one of two subgroups stratified by TMEM45A expression.
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http://www.biomedcentral.com/1471-2407/12/391DNA fragmentation. As observed in Figure 3B, the nega-
tive control siRNA did not influence DNA fragmenta-
tion, whereas TMEM45A siRNA transfection induced a
strong and significant increase in DNA fragmentation in
cells incubated with paclitaxel under normoxia or hyp-
oxia compared to non transfected cells incubated in the
same conditions.
These results clearly demonstrated for the first time an
implication of TMEM45A as an anti-apoptotic protein.
TMEM45A is also involved in the hypoxia-induced
protection of HepG2 cells against etoposide-induced
apoptosis
In order to further confirm the role of TMEM45A in drug
resistance, we used another experimental model: HepG2
hepatocellular carcinoma cells exposed to etoposide. We
have previously shown that hypoxia protected HepG2
human hepatoma cells against etoposide-induced apop-
tosis. HIF-1 and AP-1 were shown to participate to this
protective effect [32]. Using siRNA targeting TMEM45A,
we determined if TMEM45A could also be involved in the
protection of HepG2 cells against apoptosis induced by
etoposide under hypoxia.
TMEM45A mRNA expression was shown to be
increased by 5.5 fold in HepG2 cells incubated under
hypoxia in the presence or in the absence of etoposide
(Figure 4A). This increase correlated with the protective
effect of hypoxia against etoposide-induced apoptosis.
We then determined that a concentration of 50 nM of
TMEM45A siRNA was high enough to specifically in-
hibit TMEM45A mRNA expression while the RISC-Free
control siRNA had no effect.
Caspase 3 activity was then assessed in HepG2 cells
transfected with TMEM45A or negative control siRNAbefore being incubated under normoxia or hypoxia in
the presence or in the absence of etoposide. Figure 4B
shows that transfection with TMEM45A siRNA signifi-
cantly increased caspase 3 activity in cells incubated with
etoposide under hypoxia, reaching level similar to the
one observed in cells transfected with the negative con-
trol siRNA and incubated in normoxia with etoposide.
No modification was observed in control cells and in
cells incubated with etoposide under normoxia. This
indicated that the protection conferred by hypoxia
requires TMEM45A.
TMEM45A overexpression is associated with a high risk of
breast cancer recurrence
In order to validate these findings, we performed survival
analysis using the Kaplan-Meier method on data from a
study involving 286 patients with primary breast cancer
and available clinical parameters [35]. These patients
were allocated to one of two subgroups of 143 patients
stratified by TMEM45A expression.
Kaplan-Meier graph compares the disease-free survival
for groups of patients with high and low TMEM45A ex-
pression (Figure 5). The results showed that patients
whose tumors had high TMEM45A expression had a sig-
nificantly lower relapse-free survival than those whose
tumors had a low TMEM45A expression (p < 0.01). This
indicates that TMEM45A may influence cancer cell sur-
vival or growth.
TMEM45A is induced in differentiating keratinocytes
MDA-MB-231 and HepG2 cells are from epithelial ori-
gin. In both cell lines, TMEM45A plays a role in resist-
ance to apoptosis. On the other hand, differentiated
keratinocytes are also known to be resistant to che-
motherapeutic agents [36]. We thus sought whether
TMEM45A would also be expressed in such normal epi-
thelial cells. Keratinocytes in culture are a good model
for that purpose because they can easily be differentiated
in culture with a simultaneous growth arrest [37].
TMEM45A expression both at mRNA and protein levels
markedly increased between undifferentiated proliferating
cells and growth arrested differentiated cells (Figure 6A
and B). It has to be noted that the induction of TMEM45A
expression in keratinocytes exposed to hypoxia varies
according to their differentiation state. TMEM45A expres-
sion in keratinocytes at sub-confluence (C-2) is inducible
by hypoxia (by 2.92±0.92 fold after 16 hours and by
3.28±0.77 fold after 24 hours, n=3). However, this is not
the case in post-confluent, differentiated keratinocytes:
TMEM45A was not induced by hypoxia, probably because
its expression was already very high.
Induction of TMEM45A expression was also observed
when differentiation was induced by high calcium con-
centration at low cell density rather than by confluence
Figure 6 Analysis of TMEM45A gene expression level in normal human keratinocytes in vitro and in vivo. (A and B) Keratinocytes were
cultured in autocrine conditions (C-2d, 2 days before culture confluence; C, confluence; C + 2d, 2 days after confluence; C + 4d, 4 days after
confluence). (A) Total RNA has been extracted and retro-transcribed into cDNA. A real time PCR has been performed with specific primers for
TMEM45A and for TBP and RPL0 for normalization. Results are expressed as induction level by comparison with the reference condition “C-2d”.
Results are expressed as means ± 1 SD for n = 3, keratinocytes obtained from three different normal donors. ** = significantly different from C-2d
(p < 0.01). (B) TMEM45A protein level was assessed by western blot analysis. RPL13a was used as the loading control. (C) Keratinocytes were
cultured at low density in the presence of low (0.06 mM) or high (1.5 mM) calcium concentration for 48 hours. Total RNA has been extracted and
retro-transcribed into cDNA. A real time PCR has been performed with specific primers for TMEM45A and for TBP and RPL0 for normalization.
Results are expressed as induction level by comparison with undifferentiated cells (0.06 mM calcium). Results are expressed as means ± 1 SD for
n = 3, keratinocytes obtained from three different normal donors. *** = significantly different from low calcium concentration ((p < 0.001, paired
Student’s t test). (D) Immunohistological staining for TMEM45 in sections of human normal skin section with (b and c) or without primary
antibody (a).
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gical staining performed on human skin sections as indi-
cated by a higher expression of TMEM45A in the upper
layers of the epidermis (Figure 6D). TMEM45A expres-
sion was not higher in the basal layer despite the fact
that the basal layer has been shown to be in a more hyp-
oxic environment [38,39].
Discussion
Despite new discoveries of the molecular alterations that
lead to tumorigenesis and the development of new treat-
ments and therapeutic strategies against cancer, primary
treatment failure and relapse after treatment are com-
mon and death caused by cancers remains too frequent.
The development of resistance to chemotherapy repre-
sents significant obstacles to treatment of malignancies
relying on conventional cytotoxic agents. Tumor hypoxia
is often associated with chemoresistance and with an
increased probability of tumor recurrence and death.
MDA-MB-231 breast cancer cells were used for studying
the effect of hypoxia on apoptosis induced by paclitaxel
and epirubicin, two commonly used chemotherapeutic
agents. We observed that hypoxia differentially influenced
apoptosis in these cells according to the chemotherapeutic
agent. Indeed, in the presence of paclitaxel, apoptosis
was inhibited by hypoxic conditions, this was not the case
for epirubicin.
Modifications in gene expression induced by an hyp-
oxic environment have already been described to induce
resistance to radio- and chemotherapies [40], and al-
though the mechanisms underlying the development of
this resistance are partially understood, the most import-
ant mechanisms and associated biological pathways re-
main unknown.
In order to identify mechanisms responsible for the
resistance induced by hypoxia, we performed genome-
wide gene expression analyses using the Affymetrix
technology. We classified the genes whose expression
correlated best with drug resistance and i.e. with an in-
duction under hypoxia, with or without paclitaxel, that
was lower under normoxia in the presence of paclitaxel.
Thirty one genes whose expression meets these criteria
were selected. The list of these genes included known
hypoxia-responsive targets such as ALDOC [41], PFKFB4
[42], PDK1 [43], BNIP3 [44], NDRG1 [45], ENO2 [46],
PFKFB3 [47] and JMJD1A [48]. The list also includes
TMEM45A, a gene encoding a putative transmembrane
protein of unknown function. TMEM45A was previously
found to be upregulated in hypoxia in umbilical cord
blood CD133+ cells [46]. We showed that TMEM45A
expression was also induced by hypoxia in MDA-MB-
231 cells, in a HIF-1-dependent manner since HIF-1α si-
lencing prevented the hypoxia-induced upregulation.
Sheffer et al. previously showed that TMEM45A wasupregulated by zinc, that was used to induce the hypoxic
pathway, in colon cancer cells [49]. Benita et al. used
combined computational and experimental approaches
to show that TMEM45A is a bona fide HIF-1 target gene
[34]. In this study, we showed that TMEM45A renders
cancer cells resistant to different agents used in chemo-
therapy. TMEM45A silencing reverted the hypoxia-
induced protection against paclitaxel-induced apoptosis
in MDA-MB-231 cells. We confirmed the role of
TMEM45A in drug resistance, in HepG2 cells exposed
to etoposide. In this model, hypoxia also protects cells
against etoposide-apoptosis. We found again that the ex-
pression profile of TMEM45A paralleled the resistance
profile. Finally, its silencing also completely suppressed
the protection against etoposide-induced apoptosis.
TMEM45A thus exerts an anti-apoptotic function that
prevents cell killing.
Similar approaches using small interfering RNA have
already been used in order to better understand the
regulatory mechanism underlying chemotherapy resist-
ance in various cancer cell types. siRNA directed against
Ribophorin II (RPN2), which is part of an N-
oligosaccharyl transferase complex, were tested by
Honma et al. for their ability to promote apoptosis of
docetaxel-resistant MCF7-ADR breast cancer cells and
were shown to hypersensitized these cells to the che-
motherapeutic agent [50]. Specific siRNA was used to
suppress the expression of survivin, a member of the in-
hibitor of apoptosis protein (IAP) family overexpressed
in tumor cells, helping to reverse cisplatin-resistance of
A549/DDP multidrug-resistant human lung adenocarcin-
oma cells [51]. Finally, siRNA-mediated silencing of
ERCC1 (excision repair cross complementing group 1)
sensitized human colorectal cancer cells to oxaliplatin-
induced cell death [52]. Conversely, overexpression of
gene associated with resistance decreased sensitivity to
drugs. This was for example shown for another trans-
membrane protein encoding gene, TMEM205. Indeed,
an elevated expression of TMEM205 in human cisplatin-
resistant cells was associated with cisplatin resistance
and ectopic expression of TMEM205 in the cisplatin-
sensitive parental cells was shown to confer resistance to
cisplatin [53].
The function of TMEM45A is unknown. Our results
show that it has an anti-apoptotic function but its mech-
anism of action remains to be unraveled. Two hypoth-
eses can be proposed: (i) Our results show that
TMEM45A protein is induced upon differentiation of
keratinocytes, which coincides with an arrest of cell pro-
liferation. Cycling cells are known to be more sensitive
to topoisomerase inhibitors such as etoposide, notably
because these inhibitors induce less DNA damage in
non-dividing cells. However, we show here that
TMEM45A is associated with hypoxia-induced resistance
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prevent etoposide-induced DNA damage, neither does it
accelerate their reparation [24]. (ii) TMEM45A is
expressed in epithelial-derived cancer cells and highly
expressed in differentiated keratinocytes, suggesting that
it is involved in the normal function of growth arrested
epithelial cells. One family of enzymes typically
expressed in epithelia is the transglutaminase family.
These enzymes have been associated with chemoresis-
tance by at least two mechanisms: constitutive activation
of the focal adhesion kinase and formation of a ternary
complex with IκB/p65-p50 leading to activation of the
transcription factor NF-κB. Both proteins are known to
exert pro-survival activities [54]. A recent work demon-
strated that transglutaminase 2 is inducible by hypoxia
and suppresses apoptosis by modulating caspase 3 and
NF-κB activity [55]. TMEM45A could inhibit apoptosis
by promoting the expression of transglutaminase. Alter-
nately, TMEM45A may have a function similar to that of
TMEM205. This other transmembrane protein was
shown to be co-localized with RAB8, a small endosomal
recycling GTPase [56]. Members of this family of
GTPases are important regulators of intracellular mem-
brane sorting. In particular, they are thought to mediate
membrane transport specificity. Association of TMEM205
with RAB8 could lead to reduced accumulation of cis-
platin resulting in cellular resistance to the compound.
Whether TMEM45A plays a similar role in MDA-MB-231
and HepG2 cells is not known.
A Kaplan–Meier survival plot was constructed from
data from 286 lymph node–negative breast cancer
patients who had not received adjuvant systemic
treatment. We observed that high TMEM45A expression
in primary breast tumors present a higher risk of
cancer recurrence.
Conclusions
Much has been learned in recent years regarding the
genetics and molecular pathophysiology of breast cancer.
However, chemoresistance is still a heavy burden in can-
cer patient treatment, and thus it represents a difficult
challenge for future improvement of chemotherapy ef-
fectiveness. Therefore, a better understanding of the mo-
lecular mechanisms of breast cancer resistance should
help to improve patient survival. The clinical significance
of our findings is that high TMEM45A expression could
be used as a molecular prognostic marker to identify
patients who have an increased risk of cancer relapse
after chemotherapy.
Methods
Cell culture and hypoxia incubation
MDA-MB-231 human breast cancer cells and HepG2
human hepatoma cells were maintained in culture in 75-cm2 polystyrene flasks (Costar) with respectively 15 ml
of Roswell Park Memorial Institute medium (RPMI
1640, Invitrogen) or Dulbecco’s modified Eagle’s medium
(DMEM), containing 10% of fetal calf serum (Invitrogen)
and incubated under an atmosphere containing 5% CO2.
Primary culture of human skin keratinocytes was per-
formed in autocrine culture as described in Minner et al.
[37]. After written informed consent of patients (Dr
Bienfait, Clinique St Luc, Namur-Bouge, Belgium), nor-
mal human abdominal skin samples were obtained from
plastic surgery. The Medical Ethical Committee of Clini-
que St Luc, Namur-Bouge, approved all described stud-
ies, and all experiments were carried out according to
the Declaration of Helsinki Principles. In autocrine cul-
ture, keratinocytes proliferate until the confluence of the
culture is reached concomitantly with cell growth arrest
and differentiation. To study high calcium concentration
effect, keratinocytes were seeded at very low cell density.
The next day, complete medium was changed and
replaced by complete medium with 1.5 mM of calcium
or normal medium that contains 0.06 mM of calcium.
For hypoxia experiments (1% O2), cells were incubated
in serum-free CO2-independent medium (Invitrogen)
supplemented with 1 mM L-glutamine (Sigma) with or
without paclitaxel (Invitrogen) at 50 μM, epirubicin (Cal-
biochem) at 10 μM or etoposide (Sigma) at 50 μM. Nor-
moxic control cells were incubated in the same
conditions but in normal atmosphere (20% O2).
siRNA transfection
Silencing of TMEM45A or HIF-1α expression was achieved
using siGENOME SMARTpool human TMEM45A (#M-
021085-00 containing a mix of 4 siRNA: CAAUGUACUU
CUGGAGCUA, GGGAAAUGCUGGACAUCUU, AAGC
GAACCUGCUAUCUUG, UAAACAAGGUCACUGGAAU) or
HIF1A (#M-004018-05 containing a mix of 4 siRNA: CGU
GUUAUCUGUCGCUUUC, GAUGAAAGAAUUACCGAAU,
GAUGGAAGCACUAGACAAA, GGACACAGAUUUAGA
CUUG from Dharmacon. RISC-free control siRNA
purchased from Dharmacon was used to control for non-
specific effects. For siRNA experiments, 2x106 cells were
seeded in 75-cm2 polystyrene flasks (Costar) with 10 ml of
medium containing 10% of fetal calf serum. Cells were then
transfected 24 hours under standard culture conditions with
50 nM siRNA using the DharmaFECT 1 (Dharmacon)
transfection reagent according to the manufacturer's
instructions.
The transfection media were removed and replaced by
culture media for 8 hours. Cells were then trypsinized
and seeded at the appropriate density.
Caspase 3 activity
The fluorogenic substrate Ac-DEVD-AFC was used to
measure caspase 3 activity according to Cosse et al. [25].
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The « cytotoxicity detection kit » from Roche Molecular
Biochemicals was used to measure lactate dehydrogenase
(LDH) release according to the manufacturer’s protocol.
DNA fragmentation
The measurement of cytoplasmic histone-associated DNA
fragments (mono- and oligonucleosomes) after induction of cell
death was performed with the«cell death detection ELISA»(
Roche Molecular Biochemicals). Data were normalized for the
protein content determined by a BioRad protein assay.
Visualization of DAPI-labelled nuclei
35,000 cells were seeded on glass coverslips in 24-well
culture plates. 24 hours later, cells were incubated under
normoxia or hypoxia with or without paclitaxel or epiru-
bicin for 16 hours. Medium was then removed and cells
were fixed for 10 min with PBS containing 4% parafor-
maldehyde and then washed 3 × 5 min in PBS. Cells were
then permeabilized with 0.2% Triton X-100 in PBS. After
5 min, 5 μl of DAPI (10 μg/ml) (Sigma, St Louis, USA)
were added in well. After 15 min of incubation in dark at
37°C, cells were washed with PBS. Then, the coverslips
were mounted in Mowiol (Sigma, St Louis, USA) and
observed with a fluorescence microscope at 352 nm.
Real time RT-PCR
After the incubation, total RNA was extracted using the
Total RNAgent extraction kit (Promega). mRNA con-
tained in 2 μg total RNA was reverse transcribed using
SuperScript II Reverse Transcriptase (Invitrogen) and oligodT
primers according to the manufacturer’s instructions. For-
ward and reverse primers for TMEM45A were designed
using the Primer Express 1.5 software (Applied Biosystem).
Amplification reaction assays contained 1x SYBR Green PCR
Mastermix (Applied Biosystem) and primers (Applied Biosys-
tems) at the optimal concentrations. RPL13A was used as
the reference gene for normalization in MDA-MB-231 and
HepG2 cells while the geometric mean of the ct for TBP and
RPLP0 was used for keratinocytes and mRNA expression
level was quantified using the threshold cycle method.
Western blot
After the incubation, cell lysates were recovered, proteins were
separated by electrophoresis on NuPAGE gels and TMEM45A
was revealed by western blot according to Mathay et al. [57].
Anti-TMEM45A antibody was diluted 1/1000 (Sigma,
#HPA024082). RPL13 was used as loading control (anti-
RPL13 antibody diluted 1/2000, Cell Signaling #27655).
Immunohistochemical staining of human skin sections
Labeling of section of normal human skin was performed
according to Mathay et al. [57], using the same anti-
TMEM45A antibody as for the western blot analysis.Affymetrix
At the end of the incubation, total RNA was extracted
using the Trizol extraction kit (Invitrogen). RNA concen-
tration and purity were determined spectrophotometric-
ally using the Nanodrop ND-1000 (NanoDrop Products).
RNA integrity was assessed using an Agilent 2100 Bioa-
nalyser (Agilent). All the steps, including cRNA target
preparation, hybridization to Affymetrix HG-U133 Plus
2.0 arrays, washing and array signal acquisition were per-
formed according to the manufacturer’s protocol (Affy-
metrix) by DNAVision service provider based in Belgium
(http://www.dnavision.com/). Total RNA spiked with
bacterial RNA transcript positive controls was converted
to double-strand cDNA in a reverse transcription reac-
tion. Sample was then converted and amplified to anti-
sense cRNA, labeled with biotin, in an in vitro
transcription reaction. Fragmented biotinylated cRNA
and hybridization controls (Affymetrix) were hybridized
on array followed by washing and staining steps accord-
ing to the manufacturer’s procedures. The hybridized
probe array was then scanned using the GeneChipW
Scanner 3000. Data have been deposited at GEO under
accession number GSE39042.
Statistics
SigmaStat software (Jandle Scientific, Germany) was used
for the statistical analysis. Data are presented as means ±
SD and were evaluated by one-way ANOVA, using the
Holm-Sidak method.
For Affymetrix data normalization, we followed the
procedure published by Pierre et al. [58]: probe-level data
were normalized and gene expression summaries were
computed for each probe set using GeneChip Robust
Multichip Analysis (GC-RMA) [59] in the R statistical
environment (http://R-project.org). To process the data-
sets and in order to avoid inconsistencies, we did not
choose CDF (Chip Definition File) but alternative CDFs
from AffyProbeMiner, as recommended by Liu et al.
[60]. Microsoft Excel was used to calculate average ratios
and their standard deviations (S.D.) between CTL condi-
tion and the other conditions and between H tax and N
tax conditions. p values were also calculated between
these conditions. The data set was then filtered for low
expression value and calls exhibiting values under an ar-
bitrary threshold value of 8.84 (twice the value of the
basal intensity) were considered ‘absent’ otherwise calls
were considered ‘present’. Genes were finally considered
‘present’ if they had been assigned a present call in at
least two of the three biological replicate samples and
could thus be considered to be expressed genes. Fold
changes calculated with ‘absent’ gene were considered as
‘qualitative’ difference.
To obtain the dendrogram, unsupervised hierarchical
clustering by sample was performed on all probe sets
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and BRB-ArrayTools Development Team with centered
correlation as distance metric and average linkage as
linkage function.
For survival analysis, we searched GEO (http://www.
ncbi.nlm.nih.gov/geo/) for studies publishing data with
available clinical information. The gene expression data
were downloaded from 286 individuals with lymph node–
negative breast cancer who had not received adjuvant sys-
temic treatment [35] from GEO (accession number 2034).
The downloaded data were GC-RMA normalized in the R
statistical environment (http://R-project.org). Survival ana-
lysis was performed using the Kaplan-Meier method and
SigmaStat software was used to determine Kaplan-Meier
probability of relapse-free survival for the 286 patients allo-
cated to one of two subgroups of 143 patients stratified by
TMEM45A expression. The Gehan-Breslow test was used
to compare the curves and a p value <0.05 was considered
as statistically significant.
Additional file
Additional file 1: Figure S1. Hierarchical clustering of samples data
using all genes with centered correlation and average linkage. Samples
are clustered on the horizontal axis, with the vertical axis representing the
degree of correlation between samples.
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